Purpose: The pharmacology, efficacy, and safety of etravirine and its clinical utility with respect to the available alternative human immunodeficiency virus (HIV) treatment options are reviewed.

BOSTON--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for cancer and autoimmune diseases, today announced it ...

Human immunodeficiency virus (HIV) has claimed more than 40 million lives since 1981 and is still a global epidemic, despite major advances in care. Globally, in 2021, there were ~38 million people ...

Retrotransposons could have a main role in the development of drug resistance in response to cancer treatment, according to a new study out of the Roswell Park Comprehensive Cancer Center. The ...

Gilead and Merck announce positive phase 3 results for once-weekly oral islatravir/lenacapavir, demonstrating noninferiority in virologically suppressed HIV.

The combination of islatravir and lenacapavir targets multiple stages of HIV-1 replication, potentially offering people with ...

The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an ...

Combination tobevibart 300 mg + elebsiran 200 mg q4w achieved HDV RNA TND in 77% at week 72 and 88% at week 96, outperforming tobevibart monotherapy. Profound HBsAg lowering occurred with dual therapy ...

Diabetes mellitus affects more than 10% of people with HIV, and its incidence is rising as the population ages, according to the National Institutes of Health. Antiretroviral therapies that treat HIV ...